Elite in Primary Mediastinal B-Cell Lymphoma (PMBCL)

Emanuele Zucca

Bellinzona, TI, CH 
Elite in Primary Mediastinal B-Cell Lymphoma (PMBCL)
Bellinzona, TI, CH 
OverviewLocationsClinical Research

Overview

Emanuele Zucca practices in Bellinzona, Switzerland. Mr. Zucca is rated as an Elite expert by MediFind in the treatment of Primary Mediastinal B-Cell Lymphoma (PMBCL). His top areas of expertise are B-Cell Lymphoma, Non-Hodgkin Lymphoma, Marginal Zone Lymphoma (MZL), Tissue Biopsy, and Splenectomy.

His clinical research consists of co-authoring 257 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 8 articles and participated in 1 clinical trial in the study of Primary Mediastinal B-Cell Lymphoma (PMBCL).

Gender
Male

Locations

Bellinzona, TI, Switzerland
Other Locations
Bern, BE, Switzerland
Lugano, TI, Switzerland
Switzerland
Lausanne, VD, Switzerland
Manno, TI, Switzerland
Aarau, AG, Switzerland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase II Study of R-CHOP With Intensive CNS Prophylaxis and Scrotal Irradiation in Patients With Primary Testicular Diffuse Large B-cell Lymphoma
A Phase II Study of R-CHOP With Intensive CNS Prophylaxis and Scrotal Irradiation in Patients With Primary Testicular Diffuse Large B-cell Lymphoma
Enrollment Status: Completed
Publish Date: May 30, 2025
Intervention Type: Drug
Study Drugs: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, liposomal cytarabine, methotrexate
Study Phase: Phase 2
Randomized Phase II Trial on Fitness- and Comorbidity- Tailored Treatment in Elderly Patients With Newly Diagnosed Primary CNS Lymphoma (FIORELLA Trial)
Randomized Phase II Trial on Fitness- and Comorbidity- Tailored Treatment in Elderly Patients With Newly Diagnosed Primary CNS Lymphoma (FIORELLA Trial)
Enrollment Status: Completed
Publish Date: January 30, 2025
Intervention Type: Drug, Radiation
Study Drugs: Rituximab, Methotrexate, Procarbazine, Lenalidomide, Temozolomide
Study Phase: Phase 2
IELSG37: A Randomized, Open-label, Multicentre, Two-arm Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma (PMLBCL)
IELSG37: A Randomized, Open-label, Multicentre, Two-arm Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma (PMLBCL)
Enrollment Status: Active_not_recruiting
Publish Date: October 24, 2024
Intervention Type: Radiation, Other
Study Phase: Not Applicable
MALIBU Trial - Phase II Study of Combination Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas
MALIBU Trial - Phase II Study of Combination Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2024
Intervention Type: Drug
Study Drugs: Ibrutinib, Rituximab
Study Phase: Phase 2
Rituximab With or Without Ibrutinib for Untreated Patients With Advanced Follicular Lymphoma in Need of Therapy. A Randomized, Double-blinded, SAKK and NLG Collaborative Phase II Trial.
Rituximab With or Without Ibrutinib for Untreated Patients With Advanced Follicular Lymphoma in Need of Therapy. A Randomized, Double-blinded, SAKK and NLG Collaborative Phase II Trial.
Enrollment Status: Terminated
Publish Date: March 13, 2024
Intervention Type: Drug
Study Drugs: Ibrutinib, Rituximab
Study Phase: Phase 2
Combination of Ibrutinib and Bortezomib Followed by Ibrutinib Maintenance to Treat Patients With Relapsed and Refractory Mantle Cell Lymphoma; a Multicenter Phase I/II Trial.
Combination of Ibrutinib and Bortezomib Followed by Ibrutinib Maintenance to Treat Patients With Relapsed and Refractory Mantle Cell Lymphoma; a Multicenter Phase I/II Trial.
Enrollment Status: Terminated
Publish Date: March 11, 2022
Intervention Type: Drug
Study Drugs: Ibrutinib, Bortezomib
Study Phase: Phase 1/Phase 2
Integrated Molecular and Clinical Profiling to Optimize Outcome Prediction in Splenic Marginal Zone Lymphoma
Integrated Molecular and Clinical Profiling to Optimize Outcome Prediction in Splenic Marginal Zone Lymphoma
Enrollment Status: Completed
Publish Date: June 07, 2021
Prospective Collection of Data in Pts With Peripheral T-Cell Lymphoma: PTCL,NOS;AITL; Extranodal NK/T-cell;Enteropathy-type; Hepatosplenic γ-δ; Subcutaneous Panniculitis-like; ALCL,Primary Systemic Type. By the Intl. T-Cell Lymphoma Project
Prospective Collection of Data in Pts With Peripheral T-Cell Lymphoma: PTCL,NOS;AITL; Extranodal NK/T-cell;Enteropathy-type; Hepatosplenic γ-δ; Subcutaneous Panniculitis-like; ALCL,Primary Systemic Type. By the Intl. T-Cell Lymphoma Project
Enrollment Status: Completed
Publish Date: July 08, 2019
View 7 Less Clinical Trials

257 Total Publications

IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas.
IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas.
Journal: bioRxiv : the preprint server for biology
Published: July 14, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Zucca's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 18 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile